Here is the design of a clinical trial:

Official Title: PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Experimental group', 'type': 'EXPERIMENTAL', 'description': 'Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.', 'interventionNames': ['Biological: Convalescent plasma']}
- {'label': 'Control group', 'type': 'NO_INTERVENTION', 'description': 'Standard of care'}

Interventions:
- {'type': 'BIOLOGICAL', 'name': 'Convalescent plasma', 'description': 'Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.', 'armGroupLabels': ['Experimental group']}

Primary Outcomes:
- {'measure': 'Transfusion-related Serious Adverse Events', 'description': 'Incidence of transfusion-related Serious Adverse Events, according to the Hemovigilance Module Surveillance Protocol v2.5.2', 'timeFrame': '14 days after randomization'}

Please estimate the sample size based on the assumption: 
confidence level of 95%, power of 80%, drop-out rate of 10%
Numbers to be randomized (sample size)
          The sample size was calculated using the Fleiss formula with continuity correction to detect a mortality reduction from 50 to 20% between the two treatment arms with a confidence level of 95% and a power of 80%. Based on this information, a total of 45 patients per arm would be needed. After adjustment for a drop-out rate of 10% after enrolment, a total of 50 patients per arm (100 patients in total) will be enrolled.